Pharma companies are seeking to bolster pipelines and cut costs more than ever before in preparation for looming patent expirations of blockbuster drugs. In this environment global collaborations are increasing while budgets are shrinking, and as a result Internet-based communication has taken a prominent position in clinical development.
In contrast to the rapid changes in the structure of development teams and the advancements in web-based communications tools, the progress toward completely paperless clinical trials has been notably slow. Are we about to turn the corner and see new momentum? In over two decades since the first remote data entry systems were introduced, interfaces and speed of computer-based systems have improved greatly, yet the challenges of managing the paper distribution, collection and management of clinical regulatory documents in clinical trials persists.
Discussion includes:
The push for paperless continues: A look at the latest trends and initiatives
Clinical studies end-to-end: Which parts of the process are farthest along and which have the highest hurdles
Who benefits? Views on the benefits and burdens of transitioning to paperless for sites, sponsors, regulators and others
Where from here? Practical next steps towards the paperless trial
More Webcasts
Live Webcast Replay: An Outlook on Global M&A Activity
As dealmakers across the world re-enter the M&A marketplace, there is regional disparity. Professionals in Europe and the US, though more confident, have yet to see a large increase in dealmaking, whereas Asia-Pacific practitioners are riding high on the crest of a new wave of activity. With such differences, it is important for those involved in M&A to understand the global picture in order to identify and maximize opportunities.
In advance of the release of the latest IntraLinks survey entitled "Global M&A Survey - An Outlook on Global M&A Activity and Future Deal Flow", mergermarket and IntraLinks are hosting this complimentary webcast featuring expert speakers who will examine the report's key findings and discuss the latest trends in the global M&A landscape.
Live Panel Discussion Replay: The Globalization of Clinical Trials - The Good, The Bad & The Overall Impact on Pharma Development
The last decade has seen the proliferation of multinational clinical trials having sites in six or more countries, often spanning two or even three continents. The expansion of clinical trials to previously untapped locations has had many benefits:
Improved ability to maintain strong recruitment rates
Advanced capability to file/launch a new drug in many markets quickly
Live Webcast Replay: Better Execution, Earlier: Accelerating Deal Preparation and Pre-Due Diligence
Learn how leveraging the IntraLinks Deal Team Exchange can make the deal process faster, more efficient, and less cumbersome. In this interactive webcast, our sales engineer walks you through how using a Deal Team Exchange can get the team up and running to keep the process on track. This includes a deep dive in the key functionality for accelerating deal preparation and pre-due diligence.
Interview: Thomas Sabatino at the Argyle Chief Legal Officer Forum
Tom Sabatino delivered a keynote speech on the need for tighter integration between corporate legal teams and their law firms. In our interview with Tom, he further emphasized that collaboration is the foundation for effective management of legal departments, and that technology like IntraLinks can significantly enhance this process. See Tom's insight here.
Podcast: Inside The Records Room with Bob Little from AIIM's Info360 Conference
Bob Little, Vice President of Product Marketing at IntraLinks is interviewed by Ray Davis and Jeff Glover from Inside The Records Room at AIIM's Info360 Conference in Philadelphia, Pennsylvania. Bob and Ray discuss issues related to content and collaboration.
Cancer drug developer immatics biotechnologies prides itself on open communication. Using IntraLinks to manage due diligence, immatics showed investors they could trust the company. What resulted was the largest private biotech financing round in Germany since 2001. In the process, immatics saved time and resources, and gave investors an efficient way to review information.